DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global leader in acute care, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance of the company’s ST ...

You have full access to this article via your institution. Recently, the Program to Improve Care in Acute Renal Disease (PICARD) group compared the outcomes of different renal replacement therapy ...

Santiago and coauthors conducted a prospective, observational study to analyze the incidence of and risk factors for hypophosphatemia in critically ill children treated with continuous renal ...

Baxter was awarded FDA clearance for a device it won Emergency Use Authorization for during the beginning of the pandemic. The Deerfield, IL-based company said it has received a nod from FDA for the ...

Both the HF20 Set and ST Set are pre-connected disposable sets used with Baxter’s Prismaflex and PrisMax monitors, and work with all CRRT modalities and most commonly used anti-coagulants. The HF20 ...

Continuous and intermittent renal replacement therapies for patients with acute kidney injury (AKI) are associated with similar outcomes, data show. Robert L. Lins, MD, of Ziekenhuis Netwerk Antwerpen ...

A new case report details the successful use of hemoadsorption alongside continuous renal replacement therapy (CRRT) to treat severe rhabdomyolysis caused by influenza B infection in a 14-year-old boy ...